OBJECTIVE: To determine whether pharmaceutical utilisation and costs change after bariatric surgery. SUBJECTS: Total population of Australians receiving Medicare-subsidised laparoscopic adjustable gastric banding (LAGB) in 2007 (n ¼ 9542). DESIGN: Computerised data linkage with Medicare, Australia's universal tax-funded health insurance scheme. Pharmaceuticals relating to obesity-related disease and postsurgical management were assigned to therapeutic categories and analysed. The mean annual numbers of pharmaceutical prescriptions for each category were compared over the 4-year period from the year before LAGB (2006) to 2 years after LAGB (2009) using utilisation incidence rate ratios (IRRs). RESULTS: The population was mainly female (77.7%) and age was normally distributed with the majority (60.7%) of subjects aged between 35-54 years. Utilisation rates decreased significantly after LAGB in the following therapeutic categories: diabetes (IRR 0.51, IRR 95% CI 0.50-0.53, mean annual cost differences per person $30), cardiovascular (0.81, 0.80-0.82, $29), psychiatric (0.95, 0.93-0.97, $13), rheumatic and inflammatory disorders (0.51, 0.49-0.53, $10) and asthma (0.78, 0.75-0.81, $9). In contrast, significantly greater utilisation was observed in the pain (1.28, 1.23-1.32, $12), gastrointestinal tract disorder (1.04, 1.02-1.07, $5) and anaemia/vitamins (2.34, 2.01-2.73, $4) therapeutic categories. When the defined categories were combined, a net reduction in pharmaceutical utilisation was observed, from 10.5 to 9.6 pharmaceuticals prescribed per person/year, and costs decreased from $AUD517 to $AUD435 per year in 2009 prices. CONCLUSION: Relative to the year before LAGB, overall pharmaceutical utilisation was reduced in the 2 years after the year of LAGB surgery, demonstrating that bariatric surgery can lead to reductions in pharmaceutical utilisation in the 'real world' setting. The greatest absolute cost reductions were observed in the therapies to treat diabetes and cardiovascular disease. Keywords: cost; economic; healthcare; pharmaceutical; bariatric surgery; gastric banding INTRODUCTION In Australia, the prevalence of individuals with body mass index (BMI) of X40 kg m À 2 is increasing twice as fast as that for the cohort with a BMI between 30-34.9 kg m À 2 , 1 with similar trends reported in the United States (US) 2 and European countries. 3 As BMI increases above the healthy range (BMI 18.5-25 kg m À 2 ), health risks increase exponentially. 4 Three out of four adults with a BMI X40 kg m À 2 have at least one obesity-related morbidity. 5 The risk of type 2 diabetes in the severely obese population is 93-fold higher in women 6 and 43-fold higher in men 7 relative to the healthy weight population. The population with either a BMI of X40 kg m À 2 or a BMI between 35-39.9 kg m À 2 with an obesityrelated morbidity is described as severely obese.
INTRODUCTION
In Australia, the prevalence of individuals with body mass index (BMI) of X40 kg m À 2 is increasing twice as fast as that for the cohort with a BMI between 30-34.9 kg m À 2 , 1 with similar trends reported in the United States (US) 2 and European countries. 3 As BMI increases above the healthy range (BMI 18.5-25 kg m À 2 ), health risks increase exponentially. 4 Three out of four adults with a BMI X40 kg m À 2 have at least one obesity-related morbidity. 5 The risk of type 2 diabetes in the severely obese population is 93-fold higher in women 6 and 43-fold higher in men 7 relative to the healthy weight population. The population with either a BMI of X40 kg m À 2 or a BMI between 35-39.9 kg m À 2 with an obesityrelated morbidity is described as severely obese.
Lifestyle and pharmacological interventions facilitate very modest and often poorly sustained weight loss in the severely obese. 8, 9 In contrast, bariatric surgery is associated with significant and sustained weight reduction, 10, 11 leading to associated reductions in the incidence of diabetes, 12,13 cardiovascular disease 14 and selected cancers, 15 improved quality of life 16, 17 and extended life expectancy. 18 While these outcomes for bariatric surgery are well recognised, in the context of limited healthcare budgets, authorities around the world consider the associated costs of intervention as well as efficacy when making healthcare priority-setting decisions. [19] [20] [21] Previous studies assessing the impact of bariatric surgery on pharmaceutical utilisation and costs in the population eligible for surgery are from the US and Sweden. Studies from the US report an overall reduction in pharmaceutical utilisation (or costs) after surgery, (relative to the preprocedural costs or to a control group) up to 6 years after bariatric surgery. This is driven primarily by the large reduction in prescriptions to treat diabetes and cardiovascular disease after surgery. [22] [23] [24] [25] [26] [27] [28] [29] [30] However, the transferability of these results to other countries, particularly those with a universal health insurance system, is uncertain. Limitations in these studies also included small sample sizes (no400) or short duration of data capture before surgery (o90 days). The Swedish Obese Subjects Study (SOS) provides the only prospectively collected database for pharmaceuticals utilised by both a bariatric surgical group and a matched control group. The SOS also observed significant reductions in diabetes and cardiovascular therapies, but found that these were offset by increased utilisation of therapies to treat gastrointestinal tract disorders (GIDs) and anaemia/vitamin deficiency, resulting in similar overall costs over 6 years. 31 The SOS results relate to data collected in the late eighties and early nineties. Changes in bariatric surgery procedures, including the widespread adoption of laparoscopic techniques since this time, 32 may limit the transferability of results to bariatric surgery today.
This study aims to determine whether pharmaceutical utilisation and the associated costs change in the short-term after bariatric surgery. Pharmaceutical data maintained by the Australian government were analysed for the total annual population of severely obese Australians undergoing Medicare-subsidized laparoscopic adjustable gastric banding (LAGB).
MATERIALS AND METHODS Subjects
The population of Australians undergoing LAGB in 2007 (n ¼ 9542) was identified by Medicare, which administers Australia's universal tax-funded health insurance scheme. Identification was based on the utilisation of Medicare Benefits Schedule item 30511 (gastric reduction or gastroplasty for morbid obesity, by any method), which is primarily utilised for LAGB. 33 
Measures
Pharmaceutical utilisation (number of prescriptions dispensed, comprising both original and repeat scripts) and cost data for the population before and after LAGB was sourced from an administrative database 34 
Analysis
Pharmaceutical data were classified into eight therapeutic categories corresponding to obesity-related disease (diabetes, cardiovascular disease, asthma, psychiatric, rheumatic and inflammatory disorders), and post bariatric surgery management (pain, anaemia and vitamin supplementation and GIDs for analysis. Therapeutic categories were based on the Anatomical Therapeutic Chemical second level (therapeutic main group) categories (Table 1) .
Pharmaceutical utilisation 'incidence rates' (mean annual number of pharmaceutical prescriptions dispensed per person) were calculated by dividing the observed population incidence for each pharmaceutical item by the study population size for each separate year. Comparison of incidence rates between the year before LAGB (2006) and year 2 after LAGB (2009) were undertaken using incidence rate ratios (IRRs). 36 An IRR equal to one implies no difference in the incidence rate between the two time points; an IRR greater than one indicates greater use after LAGB and vice versa. Standard methods were applied to calculate IRR confidence intervals and to test whether the differences in IRRs were statistically significant. 36 Pharmaceutical costs were also analysed. Mean annual costs per person were calculated by dividing the observed population cost for each pharmaceutical item by the study population size for each separate year. Cost differences and ratios between 2006 (the year before surgery) and 2009 (year 2 after surgery) were also calculated. A government healthcare payer perspective was adopted, and therefore the unit cost paid by Medicare listed within the Pharmaceutical Benefits Schedule was analysed. 34 Costs relating to consultation with doctors to prescribe pharmaceuticals, as well as copayments for pharmaceuticals by patients, were not captured in the data, and were therefore not analysed. Health sector deflators from the Australian Institute of Health and Welfare were utilised to inflate costs to the 2009 reference year 37 (1AUD: 0.99USD: 0.63GBP).
Validation analyses
An 'other' category, comprising all prescribed pharmaceuticals not captured in the eight defined therapeutic categories, was analysed to confirm that no important trends were missed. The nomination of a prepost study design enabled subjects to be utilised as their own controls, thereby avoiding potential selection bias associated with identifying nonintervention control subjects. However, changes in clinical guidelines or pharmaceutical availability/pricing over the time are potential confounders in the longitudinal analysis of healthcare utilisation and costs. To overcome this potential issue, pharmaceutical data were also analysed for two additional populations-a severely obese sample before receiving LAGB and a similar population after receiving LAGB. Table 2) .
RESULTS

Sample characteristics
The age and sex distribution of the pre-post LAGB population adopted in the primary analysis, as well as the validation populations (pre-LAGB, post-LAGB) are depicted in Table 3 . All populations were dominated by females (77.7, 78.2 and 80.4%, respectively) and age was normally distributed with the Steady decreasing trends over the 4 years (either a decrease each year or decreasing then stable) were observed in the diabetes, cardiovascular, asthma and rheumatic/inflammatory categories. Steady increasing trends (either an increase each year or increasing then stable) were observed for the pain and the anaemia/vitamins categories. Trends over time were less consistent for the psychiatric and GID categories.
When all of the predefined therapeutic categories were combined, an overall reduction in pharmaceutical use was observed after LAGB. Over the 4-year period assessed, the mean pharmaceutical utilisation rate decreased from 10.5 to 9.0 pharmaceutical prescriptions per person/year. The utilisation IRR was 0.86 (95% CI: 0.85-0.87). Associated mean annual pharmaceutical costs over the same time horizon decreased by 16%, or the equivalent of $82 (Table 4) .
Validation analyses
After the data analysed were expanded to include the 'other' therapeutic category (and therefore all available pharmaceutical data were analysed), the IRR increased to 0.90 (95% CI: 0.89-0. 
DISCUSSION
Summary
This study found that, relative to the year before LAGB, mean annual pharmaceutical utilisation was reduced in the 2 years after LAGB. The greatest differences in utilisation were observed in therapies to treat obesity-related disease, particularly diabetes and cardiovascular disease, where marked reductions were observed, although these reductions were partially offset by greater utilisation of therapies related to post bariatric surgery management.
Decreased utilisation in selected therapeutic categories after bariatric surgery Statistically significant reductions in the utilisation of therapies to treat diabetes, cardiovascular disease, asthma, psychiatric conditions and rheumatic/inflammatory disorders were observed by this study. These reductions are likely explained by a decrease in obesity-related morbidity mediated by surgically-induced weight loss. Previous studies report that bariatric surgery facilitates improvements in each of the aforementioned conditions. 12, 13, 16, 17, [38] [39] [40] [41] [42] The current study suggests that these improvements translate to rapid reductions in pharmaceutical healthcare utilisation in the 'real world' setting. Reduced pharmaceutical utilisation was replicated in all of the aforementioned categories in the validation analyses, with the exception of the psychiatric therapeutic category, where an increase was observed during the 3.5 years after LAGB relative to the same time horizon before LAGB. Previous studies report a reduction in psychiatric symptoms in the vast majority of bariatric surgery subjects after surgery, 16, 17, [43] [44] [45] [46] [47] however, there is less consistency regarding the impact of bariatric surgery on the utilisation of psychiatric pharmaceuticals.
Previous studies report an increase/no difference 16, [48] [49] [50] or a decrease 22,51,52 after bariatric surgery, including gastric bypass. This is an area requiring further research.
Increased utilisation in selected therapeutic categories after bariatric surgery Increased pharmaceutical utilisation in therapies in the anaemia/ vitamins category, to treat pain and to a lesser extent GID, were observed by this study. Increased utilisation of anaemia/vitamins medications is unsurprising, given that supplementation is recommended for patients post bariatric surgery. 53 The increase Pharmaceutical utilisation before and after bariatric surgery CL Keating et al in pain medication is potentially explained by several factors. These include: (i) pain caused by the index bariatric surgery 54 and (ii) a shift from non-steroidal anti-inflammatory drugs, which are frequently stopped after gastric banding, because they exacerbate gastrointestinal side-effects, to less effective pain medications (personal communication, John Dixon, 6 September 2012). For the GID therapeutic category, total utilisation and costs trended in opposite directions. Analysis at the drug item level revealed that this was due to a decrease in the unit price of selected drugs for peptic ulcer and gastro-oesophageal reflux disease over the time horizon assessed.
Implications
In the context of limited healthcare budgets, authorities around the world [19] [20] [21] consider both intervention effectiveness and 'costs' when making healthcare priority-setting decisions. An important issue in undertaking cost-effectiveness analysis of new interventions is to ascertain the degree to which the costs of the intervention can be offset by reductions in the future use of healthcare resources. Previous cost-effectiveness analysis consistently report that bariatric surgery is cost-effective relative to conventional therapy (diet and exercise with or without pharmacotherapy) for treating severe obesity. 55, 56 However, reliance on patient-reported and/or modelled (rather than observed) healthcare costs introduces significant uncertainty.
Mean total pharmaceutical costs associated with obesity-related disease and post bariatric surgery management (categories defined for current study, and which would typically be included in a cost-effectiveness analysis) were reduced by 7, 19 and 16% in the year of LAGB, year 1 after LAGB and year 2 after LAGB, respectively, relative to the year before LAGB. The greatest absolute cost reductions in year 2 after LAGB (relative to the year before LAGB) were observed in pharmaceuticals to treat diabetes ($30 per person annually, 47% reduction) and cardiovascular disease ($29 per person, 17% reduction). Importantly these reductions were observed for the entire population receiving bariatric surgery. Absolute cost reductions per patient would be far greater if the population analysed was restricted to subjects with type 2 diabetes or other metabolic conditions, because the health benefits attributable to weight loss are likely to be larger for these patients. Cost data presented in the current study, which quantify the impact of bariatric surgery on short-term pharmaceutical expenditure can be adopted within future cost-effectiveness analysis.
This study only examined the 2-year period following the year of bariatric surgery. A longer time horizon and expansion of costs to include outpatient and hospital costs are required to determine, if, and to what extent bariatric surgery costs are offset by the prevention of downstream obesity-related healthcare. Healthcare costs increase with the duration of obesity, 57, 58 therefore it is also necessary to compare a bariatric surgery population with a matched population receiving conventional obesity treatment. This is affirmed by previous studies from the US, which suggest that healthcare 'savings' are achieved in bariatric surgery subjects due to the prevention of escalating costs in obese-control subjects, rather than a net reduction in healthcare costs in the bariatric surgery subjects. 59 Comparisons and transferability The SOS examined pharmaceutical utilisation and costs after bariatric surgery in a universal health insurance setting. The SOS observed lower mean annual costs in the diabetes ( À 69%) and cardiovascular disease ( À 31%) therapies relative to matched conventionally-treated controls over 6 years. 31 These figures compare with reductions of 49 and 19%, respectively, for the same therapeutic categories in the current study. The smaller differences observed in the current study are most likely explained by the different comparator populations adopted; the SOS study compared bariatric surgery subjects to control subjects receiving conventional therapies, while the current study compared subjects before and after bariatric surgery. The current study also analysed trends over a shorter time frame. The SOS study found that reductions in the metabolic therapies were offset by greater costs in the surgical group in drugs to treat gastrointestinal tract disorders, anaemia and pain. The current study also observed greater utilisation in these latter therapeutic categories after LAGB, however, to a much lesser degree than the SOS, likely due to advances in surgical methods leading to decrease in the need for postsurgery therapies.
This analysis was based on healthcare utilisation data for severely obese subjects before and after LAGB in the Australian setting. Australian eligibility guidelines for bariatric surgery (including LAGB) describe indications as BMI of X40 kg m À 2 or a BMI between 35-39.9 kg m À 2 with an obesity-related morbidity. 60 The same eligibility guidelines are adopted in other settings, for example, Europe 61 and the US. 62 Therefore, before the surgery, the populations analysed in the current study are likely to meet bariatric surgery eligibility criteria elsewhere. However, all subjects in the current study received LAGB. Other bariatric surgery procedures, particularly gastric bypass are utilised more frequently globally. 32 Weight loss outcomes and clinical outcomes (such as resolution of type 2 diabetes) differ slightly between bariatric procedures; 63 therefore, results from this study may not be directly transferable to subjects receiving other bariatric procedures. The Pharmaceutical utilisation before and after bariatric surgery CL Keating et al pharmaceutical therapeutic categories reported in this study are based on the WHO Anatomical Therapeutic Chemical system. 35 This system is widely adopted and will therefore allow international comparisons.
Strengths and limitations A key strength of this study was the data source and large populations. Data analysed were observed prescription pharmaceutical dispensation data maintained by the Australian government (rather than self-reported), therefore reliability is assumed to be high. Data were sourced via linkage with the national databases; therefore complete data were retrieved for all subjects (no loss to follow-up). The population analysed was the entire population of Australians receiving Medicare-subsidized LAGB in 2007, meaning that there was no selection bias. The population reflects LAGB as delivered in the 'real world' setting, rather than in clinical trials, which are likely to represent interventions delivered in best-practice settings. The Australian universal health insurance setting, where pharmaceuticals are accessible to all, enabled healthcare utilisation to be analysed as a proxy for morbidity and morbidity change. The validation analysis enabled potential confounders relating to the impact of changes in the clinical context on healthcare to be eliminated. The longitudinal analysis of pharmaceutical data for the population before and after surgery enabled subjects to be utilised as their own controls, thereby reducing a potential selection bias associated with adopting a retrospectively identified non-intervention control population as the comparator. However, this study design was also subject to limitations. As with any longitudinal study, the mean age of subjects increased over the 4-year time horizon assessed. Older age is associated with increasing healthcare costs. 64 However, most subjects were in the age range 35-54, where an age difference of 4 years is unlikely to be associated with a marked increase in healthcare utilisation. If anything, savings estimated by this study will have been underestimated, particularly for the metabolic categories where there is a strong correlation between age and pharmaceutical utilisation. 65 Ageing is also a potential explanation for the minor increase in the utilisation of pharmaceuticals in the antineoplastic and immunomodulating agents category observed in the validation analyses. A further explanation is that cancer is a contraindication for bariatric surgery, therefore a very low rate would be expected in the year before bariatric surgery.
The key limitation of this study was the absence of BMI information for the population assessed. Therefore, it was not possible to calculate differences in BMI or weight loss outcomes after LAGB, or to determine whether there was a dose-response relationship between weight loss and reduced pharmaceutical costs.
Pharmaceutical data were provided in aggregate form, therefore it was not possible to calculate s.e. for the mean costs, or undertake hypothesis tests of cost differences between the populations. However, given the large sample sizes in both groups, the relatively large cost differences at the therapeutic category level between populations are unlikely to have arisen by chance. The aggregate nature of the data also meant that it was not possible to test for, nor adjust for any lack of independence. The IRR analyses assume statistical independence of events. As each person in the sample may have had multiple events, this may have compromised the statistical independence, and led to some underestimation of the associated confidence intervals.
Conclusion
This study analysed pharmaceutical data maintained by the Australian government for the total population of Australians receiving Medicare-subsidized LAGB in 2007 within a contemporary universal health insurance setting. Relative to the year before LAGB, overall pharmaceutical utilisation was reduced in the 2 years after LAGB, demonstrating that bariatric surgery leads to reductions in pharmaceutical utilisation in the 'real world' setting. The greatest absolute cost reductions were observed in pharmacotherapy used to treat diabetes and cardiovascular disease.
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